February 17, 2020

BSE Limited,
Department of Corporate Services,
P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
MUMBAI - 400 001.

The National Stock Exchange of India Ltd.,
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
MUMBAI - 400 051.

Dear Sir/Madam,

Sub: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Enclosed is a Press Release as regards successful completion of an inspection carried out by the U.S. FDA at the Company's Aurangabad, India facility between February 10, 2020 and February 14, 2020. The inspection concluded without any observation.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

For LUPIN LIMITED

A P Gadre

For **R. V. SATAM**
COMPANY SECRETARY
(ACS - 11973)

LUPIN LIMITED MUMBAI INDIA

Encl.: a/a

Press Release

BSE: 500257	NSE: LUPIN	REUTERS: LUPIN.BO	BLOOMBERG: LPCIN

U.S. FDA completes inspection of Lupin's Aurangabad facility with Zero observation

Mumbai, February 17, 2020: Pharma major Lupin Limited (Lupin) announced today the successful completion of an inspection carried out by the U.S. FDA at its Aurangabad, India facility. The inspection was carried out between February 10, 2020 and February 14, 2020.

The inspection concluded without any observation.

Commenting on the outcome of the inspection, **Nilesh Gupta, Managing Director, Lupin** said, "We are encouraged with the successful inspection at our Aurangabad facility. We continue to enhance our standards of quality and compliance across our manufacturing operations and remain committed to uphold the highest quality standards across all our sites".

About Lupin Limited

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women's health areas. Lupin is the third largest pharmaceutical company in the U.S. by prescriptions and in India by global revenues. The Company invests 9.6 % of its revenues on research and development.

Lupin has 15 manufacturing sites, seven research centers, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Please visit www.lupin.com for more information.
Follow us on Twitter: https://twitter.com/LupinGlobal | LinkedIn: https://www.linkedin.com/company/lupinglobal/ | Facebook: http://www.facebook.com/LupinWorld/

For further information or queries please contact –

Arvind Bothra Head – Investor Relations and Corporate Communications Email: arvindbothra@lupin.com Tel: +91-22 6640 8237	**Manjira Sharma** General Manager – Corporate Communications Email: manjirasharma@lupin.com Tel: +91-22-6640 2532